Trial Profile
A retrospective study to evaluate the efficacy and safety of concomitant therapy of Erythropoiesis Stimulating Agents (ESA) and Ruxolitinib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 23 Jul 2019
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary) ; Epoetin alfa (Primary) ; Epoetin zeta (Primary) ; Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2017 New trial record
- 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association